Your browser doesn't support javascript.
loading
Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment.
Borowsky, Jennifer; Haruki, Koichiro; Lau, Mai Chan; Dias Costa, Andressa; Väyrynen, Juha P; Ugai, Tomotaka; Arima, Kota; da Silva, Annacarolina; Felt, Kristen D; Zhao, Melissa; Gurjao, Carino; Twombly, Tyler S; Fujiyoshi, Kenji; Väyrynen, Sara A; Hamada, Tsuyoshi; Mima, Kosuke; Bullman, Susan; Harrison, Tabitha A; Phipps, Amanda I; Peters, Ulrike; Ng, Kimmie; Meyerhardt, Jeffrey A; Song, Mingyang; Giovannucci, Edward L; Wu, Kana; Zhang, Xuehong; Freeman, Gordon J; Huttenhower, Curtis; Garrett, Wendy S; Chan, Andrew T; Leggett, Barbara A; Whitehall, Vicki L J; Walker, Neal; Brown, Ian; Bettington, Mark; Nishihara, Reiko; Fuchs, Charles S; Lennerz, Jochen K; Giannakis, Marios; Nowak, Jonathan A; Ogino, Shuji.
Afiliação
  • Borowsky J; Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Haruki K; Department of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Lau MC; Conjoint Gastroenterology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Dias Costa A; School of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Väyrynen JP; Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Ugai T; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Arima K; Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • da Silva A; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Felt KD; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Zhao M; Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Gurjao C; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Twombly TS; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Fujiyoshi K; Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
  • Väyrynen SA; Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Hamada T; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Mima K; Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Bullman S; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Harrison TA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Phipps AI; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Peters U; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Meyerhardt JA; Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Song M; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Giovannucci EL; Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Wu K; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Zhang X; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Huttenhower C; Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Garrett WS; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Chan AT; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Leggett BA; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Whitehall VLJ; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Walker N; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Brown I; Department of Epidemiology, University of Washington, Seattle, Washington.
  • Bettington M; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Nishihara R; Department of Epidemiology, University of Washington, Seattle, Washington.
  • Fuchs CS; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Lennerz JK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Giannakis M; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Nowak JA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Ogino S; Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.
Clin Cancer Res ; 27(10): 2816-2826, 2021 05 15.
Article em En | MEDLINE | ID: mdl-33632927
ABSTRACT

PURPOSE:

While evidence indicates that Fusobacterium nucleatum (F. nucleatum) may promote colorectal carcinogenesis through its suppressive effect on T-cell-mediated antitumor immunity, the specific T-cell subsets involved remain uncertain. EXPERIMENTAL

DESIGN:

We measured F. nucleatum DNA within tumor tissue by quantitative PCR on 933 cases (including 128 F. nucleatum-positive cases) among 4,465 incident colorectal carcinoma cases in two prospective cohorts. Multiplex immunofluorescence combined with digital image analysis and machine learning algorithms for CD3, CD4, CD8, CD45RO (PTPRC isoform), and FOXP3 measured various T-cell subsets. We leveraged data on Bifidobacterium, microsatellite instability (MSI), tumor whole-exome sequencing, and M1/M2-type tumor-associated macrophages [TAM; by CD68, CD86, IRF5, MAF, and MRC1 (CD206) multimarker assay]. Using the 4,465 cancer cases and inverse probability weighting method to control for selection bias due to tissue availability, multivariable-adjusted logistic regression analysis assessed the association between F. nucleatum and T-cell subsets.

RESULTS:

The amount of F. nucleatum was inversely associated with tumor stromal CD3+ lymphocytes [multivariable OR, 0.47; 95% confidence interval (CI), 0.28-0.79, for F. nucleatum-high vs. -negative category; P trend = 0.0004] and specifically stromal CD3+CD4+CD45RO+ cells (corresponding multivariable OR, 0.52; 95% CI, 0.32-0.85; P trend = 0.003). These relationships did not substantially differ by MSI status, neoantigen load, or exome-wide tumor mutational burden. F. nucleatum was not significantly associated with tumor intraepithelial T cells or with M1 or M2 TAMs.

CONCLUSIONS:

The amount of tissue F. nucleatum is associated with lower density of stromal memory helper T cells. Our findings provide evidence for the interactive pathogenic roles of microbiota and specific immune cells.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Subpopulações de Linfócitos T / Fusobacterium nucleatum / Microambiente Tumoral / Infecções por Fusobacterium Tipo de estudo: Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Subpopulações de Linfócitos T / Fusobacterium nucleatum / Microambiente Tumoral / Infecções por Fusobacterium Tipo de estudo: Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article